LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

Search

AstraZeneca PLC ADR

Open

69.03 0.41

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

68.74

Max

69.25

Belangrijke statistieken

By Trading Economics

Inkomsten

1.7B

3.4B

Verkoop

-1.3B

14B

K/W

Sectorgemiddelde

27.691

56.602

EPS

0.934

Dividendrendement

2.21

Winstmarge

25.037

Werknemers

94,300

EBITDA

610M

5B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+25.48% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.21%

2.45%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

124M

217B

Vorige openingsprijs

68.62

Vorige sluitingsprijs

69.03

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

AstraZeneca PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2025, 09:36 UTC

Belangrijke Marktbewegers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29 apr 2025, 10:14 UTC

Winsten

Correction to AstraZeneca Update

29 apr 2025, 09:15 UTC

Winsten

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29 apr 2025, 08:12 UTC

Winsten

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29 apr 2025, 06:32 UTC

Winsten

AstraZeneca Sales, Earnings Rise

24 mrt 2025, 03:15 UTC

Belangrijke Marktbewegers

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17 mrt 2025, 07:42 UTC

Acquisities, Fusies, Overnames

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

12 mei 2025, 12:07 UTC

Marktinformatie

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mei 2025, 07:20 UTC

Marktinformatie

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8 mei 2025, 15:20 UTC

Winsten

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29 apr 2025, 13:09 UTC

Marktinformatie
Winsten

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29 apr 2025, 08:04 UTC

Marktinformatie
Winsten

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29 apr 2025, 06:05 UTC

Winsten

AstraZeneca 1Q Core EPS $2.49

29 apr 2025, 06:04 UTC

Winsten

AstraZeneca 1Q Net Pft $2.92B

29 apr 2025, 06:02 UTC

Winsten

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca 1Q Core EPS Consensus Was $2.27

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca 1Q Revenue Consensus Was $13.80B

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca Backs 2025 View

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca PLC 1Q EPS $1.87

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Rev $13.59B

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Oper Pft $3.67B

29 apr 2025, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Pretax Pft $3.4B

15 apr 2025, 09:55 UTC

Marktinformatie

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 apr 2025, 07:23 UTC

Marktinformatie

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 apr 2025, 08:41 UTC

Marktinformatie

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 apr 2025, 08:36 UTC

Marktinformatie

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 apr 2025, 07:51 UTC

Marktinformatie

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 mrt 2025, 09:31 UTC

Populaire aandelen

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17 mrt 2025, 14:43 UTC

Marktinformatie

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17 mrt 2025, 13:55 UTC

Marktinformatie
Acquisities, Fusies, Overnames

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

Peer Vergelijking

Prijswijziging

AstraZeneca PLC ADR Prognose

Koersdoel

By TipRanks

25.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 86.34 USD  25.48%

Hoogste 98 USD

Laagste 75 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor AstraZeneca PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

N/A / 69.55Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.